Literature DB >> 29031890

Changing perspectives in atopic dermatitis.

E Serra-Baldrich1, J O de Frutos2, I Jáuregui3, J C Armario-Hita4, J F Silvestre5, L Herraez6, A Martín-Santiago7, A Valero8, J Sastre9.   

Abstract

Atopic dermatitis (AD) is a multifaceted disease that involves a complex interplay between the skin and the immune system. The course of the disease depends strongly on the genetic background of the patient and on yet poorly-defined environmental factors. Changes in lifestyle could be behind the dramatic rise in the prevalence of AD across continents; including hygienic conditions, food, social habits, skin microbiome or exposure to a number of allergens. Although AD typically develops in childhood and disappears after a few years, in a relatively large number of patients it continues into adulthood. Adult AD can also appear de novo but it is often underdiagnosed and its treatment can be challenging. New, highly effective drugs are being developed to manage moderate and severe forms of the disease in adults. In this review, we highlight the most recent developments in diagnostic tools, current insights into the mechanistic basis of this disease, and therapeutic innovations.
Copyright © 2017 SEICAP. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Atopic dermatitis; Atopic eczema; Biological drugs; Skin barrier

Mesh:

Year:  2017        PMID: 29031890     DOI: 10.1016/j.aller.2017.07.002

Source DB:  PubMed          Journal:  Allergol Immunopathol (Madr)        ISSN: 0301-0546            Impact factor:   1.667


  2 in total

1.  Consensus on the Clinical Approach to Moderate-to-Severe Atopic Dermatitis in Spain: A Delphi Survey.

Authors:  Joaquín Sastre; Esther Serra Baldrich; José Carlos Armario Hita; L Herráez; Ignacio Jáuregui; Ana Martín-Santiago; Javier Ortiz de Frutos; Juan Francisco Silvestre; Antonio Valero
Journal:  Dermatol Res Pract       Date:  2020-04-07

2.  104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain.

Authors:  Jose Juan Pereyra-Rodriguez; Javier Dominguez-Cruz; Jose Carlos Armario-Hita; Ricardo Ruiz-Villaverde
Journal:  An Bras Dermatol       Date:  2021-09-27       Impact factor: 1.896

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.